Abstract:

Acquired reactive perforating collagenosis (ARPC) is a rare perforating skin disease, and its pathogenesis is still unclear. ARPC is rare clinically, and it is easy to be missed or be misdiagnosed. At present, there is no relevant reference guide for the diagnosis and treatment of ARPC, so antihistamine and antipruritic are the symptomatic treatments. Because this disease is often secondary to other systemic diseases, we should actively treat or control the primary diseases while treating this disease, so that this disease can be quickly controlled. A case of ARPC admitted to Affiliated Hospital of Guangdong Medical University in August 2021 is reported in this paper.

Key words:

Acquired reactive perforating collagenosis, Dermatosis, Perforating folliculitis, Keratosis follicularis et parafollicularis serpiginosa

摘要：

获得性反应性穿通性胶原病（ARPC）是一种罕见的穿通性皮肤病，其发病机制仍不清楚。ARPC临床上比较罕见，容易漏诊或误诊。目前ARPC的诊疗无相关参考指南，因此在治疗上均以抗组胺、止痒等对症治疗。由于该病常常继发于其他系统疾病，应积极治疗或控制原发病的同时治疗本病，可使本病迅速得到控制。本文报道广东医科大学附属医院2021年8月收治的1例ARPC。

关键词:

获得性反应性穿通性胶原病, 皮肤病, 穿通性毛囊炎, 匐行性穿通性弹性纤维病